Survodutide has been quietly building one of the more interesting case files in the incretin space, and last week the full data finally landed in a peer-reviewed journal. The SYNCHRONIZE-2 trial results were published in the New England Journal of Medicine alongside their presentation at the EASD meeting in Milan, and they deserve a closer look than the press release treatment they got.
The reason is simple. Weight loss in type 2 diabetes is harder than weight loss without diabetes, and any compound that puts up strong numbers in that population is telling you something about its mechanism, not just its marketing.
What the trial tested
SYNCHRONIZE-2 was a phase 3, double-blind, placebo-controlled trial that enrolled 752 adults with obesity or overweight and type 2 diabetes, randomised one-to-one-to-one to receive once-weekly subcutaneous survodutide at either 3.6 mg or 6.0 mg, or placebo, for 76 weeks. Survodutide, developed by Boehringer Ingelheim with Zealand Pharma, is a glucagon and GLP-1 receptor dual agonist, which places it mechanistically in the same family of thinking as retatrutide’s glucagon arm, but without the GIP component.
The two primary endpoints were the percentage change in body weight at 76 weeks and the proportion of participants achieving at least 5% weight reduction. The trial met both co-primary endpoints on both treatment-regimen and efficacy estimands.
What the Research Says
- Participants on survodutide achieved a mean weight loss of up to 13.1% at 76 weeks using the efficacy estimand, versus 3.1% on placebo, a statistically significant difference (p less than 0.0001).
- Up to 79.3% of participants on survodutide achieved at least 5% body weight reduction, versus 32.7% on placebo.
- The trial reported improvements in glycaemic control alongside the weight data, per Boehringer Ingelheim’s announcement of the results.
- The paper is published in the New England Journal of Medicine, October 2026, DOI 10.1056/NEJMoa2607219, with the full results presented at the 62nd EASD Annual Meeting in Milan.
Why 13.1% in this population is a bigger deal than it sounds
Context matters here. Participants in SYNCHRONIZE-2 had type 2 diabetes and an average body mass index around 36.5, with a mean age of 55.7. This is a population where GLP-1 medications have historically produced less dramatic weight loss than in people without diabetes. Semaglutide in its type 2 diabetes trials, for instance, lands meaningfully lower than the STEP 1 numbers people usually quote.
Against that backdrop, 13.1% at 76 weeks is a solid result, though it is worth being honest about where it sits. It is well above what placebo or lifestyle interventions achieve, and the nearly four in five participants clearing the 5% threshold is a meaningful proportion-response finding. But it is not in the same bracket as retatrutide’s 20.8% in the comparable TRIUMPH-2 population, or tirzepatide’s results in the SURPASS trials. Our retatrutide page and tirzepatide page have those numbers side by side.
The glucagon agonism is the interesting part of the mechanism story. Boehringer and Zealand’s bet has been that adding glucagon receptor activity drives energy expenditure, and the liver fat data from earlier survodutide studies, which we covered on the survodutide research page, suggested the compound does something meaningful in metabolic liver disease. The surviving question is whether that mechanism can push weight loss higher without pushing tolerability over the edge.
The tolerability picture
This is where survodutide’s story gets complicated. Across the survodutide programme, gastrointestinal side effects and discontinuation rates have been notably high, and SYNCHRONIZE-2 is no exception. Community discussion following the results has pointed to a meaningful share of participants stopping treatment for GI reasons, which is consistent with what the earlier SYNCHRONIZE-1 obesity trial and the phase 2 studies showed.
It is a pattern worth watching closely, because the three-way contest between efficacy, tolerability and adherence is what actually determines whether a compound works in the real world. A trial result is measured on people who were enrolled, screened and followed up. A pharmacy result is measured on whoever refills their script.
What it means in Australia
Survodutide is not approved in Australia or anywhere else, and Boehringer Ingelheim has not yet announced a submission timeline for the local regulator. For the Australian research community, the takeaways are about mechanism and positioning rather than access. The glucagon-plus-GLP-1 combination is now validated in a second large phase 3 dataset, and the next two years will tell us whether the class converges on retatrutide-style numbers or settles into a differentiated middle ground.
If you are following the compound developments as they land, the Grey Highway Telegram group is where the community breaks down each dataset as it is published, including the subanalyses that rarely make the news summaries.
Sources
Source: Wharton S, et al. “Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes”, New England Journal of Medicine, published 1 October 2026, DOI: 10.1056/NEJMoa2607219: https://www.nejm.org/doi/full/10.1056/NEJMoa2607219
Source: Boehringer Ingelheim, “Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes”, 1 October 2026: https://www.boehringer-ingelheim.com/human-health/crm-health/metabolic-health/survodutide-synchronize-2-phase-3-obesity-type-2-diabetes-results
Source: AJMC, “Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D”, 2 October 2026: https://www.ajmc.com/view/dual-agonist-survodutide-delivers-up-to-13-1-weight-loss-in-t2d
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.